CREOSG CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 897 KRW | -3.55% |
|
-2.29% | +73.84% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 978.12Cr 72.38L 60Cr | Sales 2023 | 975.62Cr 72.2L 60Cr | Capitalization | 6.48TCr 4.8Cr 399.1Cr |
|---|---|---|---|---|---|
| Net income 2022 | -1.04TCr -77.25L -64Cr | Net income 2023 | -1.17TCr -86.91L -72Cr | EV / Sales 2022 | 10.9 x |
| Net Debt 2022 | 2.26TCr 1.67Cr 139.16Cr | Net Debt 2023 | 254.28Cr 18.82L 16Cr | EV / Sales 2023 | 6.9 x |
| P/E ratio 2022 |
-8.01
x | P/E ratio 2023 |
-5.54
x | Employees | 33 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 67.41% |
More Fundamentals
* Assessed data
More news
| 1 day | -3.55% | ||
| 1 week | -2.29% | ||
| Current month | +7.43% | ||
| 1 month | +74.51% | ||
| 3 months | +106.68% | ||
| 6 months | +89.24% | ||
| Current year | +73.84% |
1 week
875.00
963.00
1 month
531.001 026.00
Current year
405.001 026.00
1 year
405.001 026.00
3 years
405.002 020.00
5 years
405.003 180.00
10 years
405.005 400.00
| Managers | Title | Age | Since |
|---|---|---|---|
Joong-Ki Cho
CEO | Chief Executive Officer | 54 | 30/04/30 |
Sung-Soo Lee
AUD | Comptroller/Controller/Auditor | 50 | 25/10/25 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
In-Chang Hwang
BRD | Director/Board Member | 54 | 24/15/24 |
Joong-Ki Cho
CEO | Chief Executive Officer | 54 | 30/04/30 |
Sun-Kook Hwang
BRD | Director/Board Member | 64 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/24/17 | 897 | -3.55% | 526,481 |
| 16/24/16 | 930 | -0.43% | 320,076 |
| 14/24/14 | 934 | +1.74% | 499,962 |
| 13/24/13 | 918 | 0.00% | 1,129,502 |
| 10/24/10 | 918 | -3.77% | 1,088,569 |
End-of-day quote Korea S.E., May 17, 2024
More quotes
CreoSG Co Ltd, formerly Curocom Co Ltd, is a Korea-based company mainly engaged in solution business and distribution business. The Company operates through three segments. The Solutions Business segment is engaged in the development and provision of financial consulting and software for financial institutions. Additionally, the segment is engaged in the supply of core banking solutions BANCS-K framework and BANCS-K Package to banks and other financial institutions. The Distribution Business segment is engaged in the distribution business of computers, laptops, printers, and multi-function printers. The New Drug and Vaccine Development Business segment is engaged in the development of vaccines for acquired immunodeficiency syndrome(AIDS), corona virus disease 19 (COVID-19) vaccine and other infectious diseases, and research and development of super antibiotics for Staphylococcus aureus.
Sector
Software
Calendar
14/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +73.84% | 9.45Cr | |
| +17.16% | 34TCr | |
| +26.91% | 22TCr | |
| +8.29% | 16TCr | |
| +12.47% | 5.76TCr | |
| +21.25% | 3.49TCr | |
| +5.99% | 3.14TCr | |
| +150.86% | 2.81TCr | |
| +30.09% | 2.17TCr | |
| +47.81% | 1.5TCr |
- Stock Market
- Equities
- A040350 Stock
